Claims for Patent: 10,172,808

Summary for Patent: 10,172,808

Title:	Combinations of mRNAs encoding immune modulating polypeptides and uses thereof
Abstract:	The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36.gamma. (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
Inventor(s):	Frederick; Joshua (Boston, MA), Bai; Ailin (Newton, MA), Presnyak; Vladimir (Cambridge, MA), Hoge; Stephen (Brookline, MA), Benenato; Kerry (Sudbury, MA), McFadyen; Iain (Arlington, MA), Kumarasinghe; Ellalahewage Sathyajith (Harvard, MA), Hewitt; Susannah (Jamaica Plain, MA)
Assignee:	ModernaTX, Inc. (Cambridge, MA)
Application Number:	15/995,889
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,172,808
Patent Claims:	1. A method for treating cancer in a subject by inducing or enhancing an anti-tumor immune response, comprising administering to the subject a first messenger RNA (mRNA) encoding an IL-23 polypeptide, a second mRNA encoding an IL-36gamma polypeptide, and a third mRNA encoding an OX40L polypeptide, thereby treating cancer in the subject by inducing or enhancing an anti-tumor immune response. 2. The method of claim 1, wherein the IL-23 polypeptide comprises an IL-12p40 polypeptide operably linked, with or without a linker, to an IL-23p19 polypeptide. 3. The method of claim 2, wherein the IL-23 polypeptide comprises an IL-12p40 polypeptide operably linked via a linker to an IL-23p19 polypeptide, and wherein the linker is a Gly/Ser linker. 4. The method of claim 1, wherein the IL-23 polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NOs: 1, 3, 4, 5 and 140, wherein the IL-36gamma polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 12, and 16, and wherein the OX40L polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2 and 21. 5. The method of claim 1, wherein (i) the first mRNA encoding an IL-23 polypeptide comprises an open reading frame, wherein the open reading frame comprises the nucleotide sequence as set forth in SEQ ID NO: 141, or a nucleotide sequence at least 90% identical to the nucleotide sequence as set forth in SEQ ID NO: 141; (ii) the second mRNA encoding an IL-36gamma polypeptide comprises an open reading frame, wherein the open reading frame comprises the nucleotide sequence as set forth in SEQ ID NO: 143, or a nucleotide sequence at least 90% identical to the nucleotide sequence as set forth in SEQ ID NO: 143; and (iii) the third mRNA encoding an OX40L polypeptide comprises an open reading frame, wherein the open reading frame comprises the nucleotide sequence as set forth in SEQ ID NO: 145, or a nucleotide sequence at least 90% identical to the nucleotide sequence as set forth in SEQ ID NO: 145. 6. The method of claim 5, wherein the first mRNA, second mRNA and third mRNA each comprise a 3' untranslated region (UTR) comprising at least one microRNA-122 (miR-122) binding site. 7. The method of claim 6, wherein the miR-122 binding site is a miR-122-5p binding site, and wherein the miR-122-5p binding site comprises the nucleotide sequence as set forth in SEQ ID NO: 26. 8. The method of claim 1, wherein (i) the first mRNA comprises the nucleotide sequence as set forth in SEQ ID NO: 142, or a nucleotide sequence at least 90% identical to the nucleotide sequence set forth in SEQ ID NO: 142; (ii) the second mRNA comprises the nucleotide sequence as set forth in SEQ ID NO: 144, or a nucleotide sequence at least 90% identical to the nucleotide sequence set forth in SEQ ID NO: 144; and (iii) the third mRNA comprises the nucleotide sequence as set forth in SEQ ID NO: 146, or a nucleotide sequence at least 90% identical to the nucleotide sequence set forth in SEQ ID NO: 146. 9. The method of claim 1, wherein the first, second and third mRNAs are chemically modified. 10. The method of claim 9, wherein the first, second and third mRNAs are fully modified with chemically-modified uridines. 11. The method of claim 9, wherein the first, second and third mRNAs are fully modified with N1-methylpseudouridine. 12. The method of claim 1, wherein the first, second and third mRNAs are formulated in separate lipid nanoparticles. 13. The method of claim 12, wherein the lipid nanoparticles are administered simultaneously or sequentially. 14. The method of claim 1, wherein the first, second and third mRNAs are formulated in the same lipid nanoparticle. 15. The method of claim 14, wherein the first, second and third mRNAs are formulated in the lipid nanoparticle at a mass ratio of OX40L:IL-23:IL-36gamma of 1:1:2. 16. The method of claim 1, comprising administering a checkpoint inhibitor polypeptide, wherein the checkpoint inhibitor polypeptide inhibits PD1, PD-L1, CTLA4, or a combination thereof, and wherein the checkpoint inhibitor polypeptide is an antibody or antigen-binding fragment thereof. 17. The method of claim 16, wherein the antibody is an anti-CTLA4 antibody or antigen-binding fragment thereof that specifically binds CTLA4, an anti-PD1 antibody or antigen-binding fragment thereof that specifically binds PD1, an anti-PD-L1 antibody or antigen-binding fragment thereof that specifically binds PD-L1, or a combination thereof. 18. The method of claim 17, wherein the anti-PD-L1 antibody is atezolizumab, avelumab, or durvalumab, wherein the anti-CTLA-4 antibody is tremelimumab or ipilimumab, and wherein the anti-PD1 antibody is nivolumab or pembrolizumab.

Details for Patent 10,172,808

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	03/25/2011		2036-05-18
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	For Injection	125514	09/04/2014		2036-05-18
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	Injection	125514	01/15/2015		2036-05-18
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	12/22/2014		2036-05-18
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	10/04/2017		2036-05-18
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	08/27/2021		2036-05-18
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034	05/18/2016		2036-05-18